New cancer drug cost-effectiveness assessment algorithm proposed by experts

…minor amendment to the Reimbursement Act, experts at Fundacja Alivia said. A report published by Alivia earlier this year claimed more than half of new cancer drugs that have been approved in Europe over the past 12 years – 50 out of 94 – are not reimbursed in Poland.  

Sign up now to open the entire news item.

You are allowed to open only one news item from PMR websites.
  • 1E-mail
    (to send requested information)
  • 2Brief profile
    (required for new e-mails only)

 required fields

You must accept PMR’s Privacy Policy.